RoslinCT is a leading contract development and manufacturing organisation (CDMO) specialising in the development and commercialisation of advanced cell and gene therapies. Established in 2006, it harnesses cutting-edge technology from the Roslin Institute and provides comprehensive solutions for the biopharmaceutical industry.

RoslinCT offers expertise in human pluripotent stem cell production, including iPSCs, and supports partners through the entire lifecycle of cell and gene therapies. It operates state-of-the-art, purpose-built cGMP facilities that support both clinical and commercial manufacturing.

Key Products and Services

• cGMP iPSC development
• Process and analytical development
• cGMP cell banking
• Manufacturing science and technology
• Clinical and commercial manufacturing
• Quality and regulatory compliance
• Supply chain and logistics

With a commitment to innovation and patient-focused solutions, RoslinCT continues to be a trusted partner in the cell and gene therapy space, advancing life-changing treatments globally.